WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205619
CAS#: NONE
Description: SAR103168 is a multikinase inhibitor with potential antineoplastic activity. Upon intravenous infusion, multikinase inhibitor SAR103168 may, through the inhibition of multiple kinases, inhibit the phosphorylation and activation of signal transducer and activator of transcription 5 (STAT5). STAT5, a protein often upregulated in cancer cells, plays a key role in signal transduction pathways and the suppression of apoptosis.
MedKoo Cat#: 205619
Name: SAR103168
CAS#: NONE
Chemical Formula:
Exact Mass:
Molecular Weight:
Elemental Analysis:
SAR103168 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: SAR103168; SAR-103168; SAR 103168.
IUPAC/Chemical Name: NONE
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F. Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma. 2015 Feb;56(2):395-400. doi: 10.3109/10428194.2014.918970. PubMed PMID: 24794806.
2: Altman JK, Szilard AK, Platanias LC. Tyrosine kinase inhibition in acute myeloid leukemia. Leuk Lymphoma. 2013 Jul;54(7):1351-2. doi: 10.3109/10428194.2012.754889. Epub 2013 Jan 10. PubMed PMID: 23206226.
3: Bourrié B, Brassard DL, Cosnier-Pucheu S, Zilberstein A, Yu K, Levit M, Morrison JG, Perreaut P, Jegham S, Hilairet S, Bouaboula M, Penarier G, Guiot C, Larroze-Chicot P, Laurent G, Demur C, Casellas P. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leuk Lymphoma. 2013 Jul;54(7):1488-99. doi: 10.3109/10428194.2012.745071. Epub 2012 Dec 3. PubMed PMID: 23121564.